Tirzepatide vs. Retatrutide: The 2026 Next-Generation GLP-1 Comparison
Last reviewed and updated: May 5, 2026 — medically reviewed by Dr. Jonathann Kuo, MD. 2026 Status: Tirzepatide (Zepbound, Mounjaro) is FDA-approved and widely available. Retatrutide — the next-generation triple-agonist GLP-1 — is in Phase 3 trials. Early results show the most potent weight loss of any GLP-1-class drug studied to date, but it’s not […]
Read More